QDEL
NASDAQQuidelOrtho Corporation
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
News · 26 weeks66+117%
2025-11-022026-04-26
Mix4890d
- Insider26(54%)
- Other9(19%)
- SEC Filings8(17%)
- Earnings2(4%)
- Leadership2(4%)
- M&A1(2%)
Latest news
25 items- INSIDEREVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 1,459 shares and covered exercise/tax liability with 528 shares, increasing direct ownership by 30% to 4,070 units (SEC Form 4) (withholding obligation)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERChief Operations Officer Mclellan Philip D. was granted 1,946 shares and covered exercise/tax liability with 699 shares, increasing direct ownership by 6% to 22,497 units (SEC Form 4) (tax liability)4 - QuidelOrtho Corp (0001906324) (Issuer)
- SECSEC Form DEFA14A filed by QuidelOrtho CorporationDEFA14A - QuidelOrtho Corp (0001906324) (Filer)
- SECSEC Form DEF 14A filed by QuidelOrtho CorporationDEF 14A - QuidelOrtho Corp (0001906324) (Filer)
- INSIDERChief Operations Officer Mclellan Philip D. was granted 3,238 shares and covered exercise/tax liability with 1,162 shares, increasing direct ownership by 11% to 21,250 units (SEC Form 4) (for tax liability)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDEREVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 3,508 shares and covered exercise/tax liability with 1,269 shares, increasing direct ownership by 249% to 3,139 units (SEC Form 4) to cover taxes4 - QuidelOrtho Corp (0001906324) (Issuer)
- PRUnderstanding and Addressing Syphilis Trends - and What's Being MissedSAN DIEGO, April 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving syphilis trends in the United States and the rise of congenital syphilis cases despite declines in early-stage infections. Hosted by Josh Casey, the episode features Andrea Ott‑Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, who breaks down what CDC data reveals, why congenital syphilis continues to rise and how diagnostic strategies and healthcare workflows can
- INSIDERSEC Form 4 filed by Sisitsky Nathaniel4 - QuidelOrtho Corp (0001906324) (Issuer)
- PRTTP Group Announces the Sale of LEX DiagnosticsTTP today announced the acquisition by QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group. Founded in 2020, LEX Diagnostics originated from a TTP innovation programme to translate a breakthrough in ultra-fast thermal control into a commercially viable diagnostic solution. This work led to the development of a point-of-care molecular testing platform capable of delivering PCR results in minutes. "At TTP, we identified the opportunity for ultra-fast thermal cycling to unlock the real potential of PCR at the point-of-care," said Dr Andrew Baker-Campbell, Chair and f
- PRQuidelOrtho Corporation Completes Acquisition of LEX Diagnostics– Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics –– Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less –– Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year –SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and
- SECQuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - QuidelOrtho Corp (0001906324) (Filer)
- PRQuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 GuidanceSAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 RevenueThe Company currently expects preliminary unaudited revenue, as reported, o
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- INSIDERSEC Form 3 filed by new insider Sisitsky Nathaniel3 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Busky Joseph M.4 - QuidelOrtho Corp (0001906324) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- INSIDERSEC Form 3 filed by new insider Hanson Bryan Michael3 - QuidelOrtho Corp (0001906324) (Issuer)
- SECQuidelOrtho Corporation filed SEC Form 8-K: Regulation FD Disclosure8-K - QuidelOrtho Corp (0001906324) (Filer)
- PRNathaniel Sisitsky Joins QuidelOrtho as Chief Legal OfficerSAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.
- INSIDERAmendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)4/A - QuidelOrtho Corp (0001906324) (Issuer)
- PRFaster Cardiac Answers with High‑Sensitivity TroponinSAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency. Key InsightsFaster answers when time matters: hs troponin detects cardiac injury earlier than traditional assays, enabling quicker diagnosis and r
- SECSEC Form 10-K filed by QuidelOrtho Corporation10-K - QuidelOrtho Corp (0001906324) (Filer)
- PRQuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor ConferenceSAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference. The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m. ET / 10:40 a.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/
- SECSEC Form 8-K filed by QuidelOrtho Corporation8-K - QuidelOrtho Corp (0001906324) (Filer)
- INSIDERDirector Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
QDEL FAQ
6 questionsWhat does QuidelOrtho Corporation do?
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes...Where does QDEL stock trade?
QuidelOrtho Corporation (QDEL) is listed on NASDAQ.What sector and industry is QDEL in?
QuidelOrtho Corporation operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about QDEL?
QuidelOrtho Corporation has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral with a $3300.00 price target on 2025-10-07. Recent price targets range from $3300.00 to $4400.00.What companies are similar to QDEL?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), NNNN (Anbio Biotechnology), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.). Compare QDEL side-by-side with any of them on Quantisnow.How can I track QDEL on Quantisnow?
Quantisnow aggregates QuidelOrtho Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QDEL to receive live email and push alerts on every new disclosure.